These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 33749049)

  • 21. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
    McDermott DF; Sosman JA; Gonzalez R; Hodi FS; Linette GP; Richards J; Jakub JW; Beeram M; Tarantolo S; Agarwala S; Frenette G; Puzanov I; Cranmer L; Lewis K; Kirkwood J; White JM; Xia C; Patel K; Hersh E
    J Clin Oncol; 2008 May; 26(13):2178-85. PubMed ID: 18445842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II study evaluating the effect of tamoxifen on DNA repair in melanoma patients treated with dacarbazine.
    Saunders MP; Salisbury AJ; O'Byrne KJ; Souliotis VL; Varcoe SM; Talbot DC; Kyrtopoulos SA; Harris AL
    Anticancer Res; 1997; 17(6D):4677-80. PubMed ID: 9494588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea.
    Philip PA; Souliotis VL; Harris AL; Salisbury A; Tates AD; Mitchell K; van Delft JH; Ganesan TS; Kyrtopoulos SA
    Clin Cancer Res; 1996 Feb; 2(2):303-10. PubMed ID: 9816173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of therapy on the antioxidant status in patients with melanoma.
    Gadjeva V; Dimov A; Georgieva N
    J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study.
    Schinzari G; Rossi E; Cassano A; Dadduzio V; Quirino M; Pagliara M; Blasi MA; Barone C
    Melanoma Res; 2017 Dec; 27(6):591-595. PubMed ID: 29076951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
    Rudolf Z; Strojan P
    Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of O(6)-methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy.
    Ma S; Egyházi S; Martenhed G; Ringborg U; Hansson J
    Melanoma Res; 2002 Aug; 12(4):335-42. PubMed ID: 12170182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC.
    Busch C; Geisler J; Lillehaug JR; Lønning PE
    Eur J Cancer; 2010 Jul; 46(11):2127-33. PubMed ID: 20541396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
    Middleton MR; Grob JJ; Aaronson N; Fierlbeck G; Tilgen W; Seiter S; Gore M; Aamdal S; Cebon J; Coates A; Dreno B; Henz M; Schadendorf D; Kapp A; Weiss J; Fraass U; Statkevich P; Muller M; Thatcher N
    J Clin Oncol; 2000 Jan; 18(1):158-66. PubMed ID: 10623706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.
    Ferrucci PF; Minchella I; Mosconi M; Gandini S; Verrecchia F; Cocorocchio E; Passoni C; Pari C; Testori A; Coco P; Munzone E
    Melanoma Res; 2015 Jun; 25(3):239-45. PubMed ID: 25746039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Docetaxel in combination with dacarbazine in patients with advanced melanoma.
    Bafaloukos D; Aravantinos G; Fountzilas G; Stathopoulos G; Gogas H; Samonis G; Briasoulis E; Mylonakis N; Skarlos DV; Kosmidis P
    Oncology; 2002; 63(4):333-7. PubMed ID: 12417787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topical CpG enhances the response of murine malignant melanoma to dacarbazine.
    Najar HM; Dutz JP
    J Invest Dermatol; 2008 Sep; 128(9):2204-10. PubMed ID: 18368132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.
    Thallinger C; Werzowa J; Poeppl W; Kovar FM; Pratscher B; Valent P; Quehenberger P; Joukhadar C
    J Invest Dermatol; 2007 Oct; 127(10):2411-7. PubMed ID: 17508024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma.
    Falkson CI
    Med Oncol; 1995 Mar; 12(1):35-40. PubMed ID: 8542245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
    Rusthoven JJ; Quirt IC; Iscoe NA; McCulloch PB; James KW; Lohmann RC; Jensen J; Burdette-Radoux S; Bodurtha AJ; Silver HK; Verma S; Armitage GR; Zee B; Bennett K
    J Clin Oncol; 1996 Jul; 14(7):2083-90. PubMed ID: 8683240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.
    Lee SM; Margison GP; Woodcock AA; Thatcher N
    Br J Cancer; 1993 Jun; 67(6):1356-60. PubMed ID: 8512821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of bio-chemotherapy with dacarbazine plus interleukin-2 in patients with unresectable malignant melanoma.
    Wu CF; Wang HM; Huang WK; Chang JW
    Asia Pac J Clin Oncol; 2015 Dec; 11(4):314-8. PubMed ID: 26310907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential dacarbazine/cisplatin and interleukin-2 in metastatic melanoma: immunological effects of therapy.
    Redman BG; Flaherty L; Chou TH; Nakeff A; Pillote K; Kaplan J
    J Immunother (1991); 1991 Apr; 10(2):147-51. PubMed ID: 2043595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.
    Hillner BE; Agarwala S; Middleton MR
    J Clin Oncol; 2000 Apr; 18(7):1474-80. PubMed ID: 10735895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.